A Phase 2 interventional study of AK104 and AK104+ Paclitaxel+Cisplatin or Carboplatin in Vulvar Cancer, sponsored by Akeso. Terminated at 6 sites in China. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Akeso · Phase 2, Interventional, and Treatment
Sponsor decision
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Vulvar Neoplasms with a site in China — 9 open to participants now, 12 under way, 3 of them phase 3. Vulvar Neoplasms · China.
Among the 21 studies in Vulvar Neoplasms with a site in China, this one is the 15th largest by enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2023, is one of 5 in phase 2, and was the 14th registered.
236 studies on the registry are indexed under Vulvar Neoplasms; 69 are open to participants now.
Browse Vulvar Neoplasms studies →9 of the 21 studies in Vulvar Neoplasms with a site in China are open now. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75 · Women only
Sichuan Enray Pharmaceutical Sciences Company · Sites in China
Ages 18–80
Zhejiang Cancer Hospital · Sites in China
Ages 18–75 · Women only
HRYZ Biotech Co. · Sites in China
Ages 18–75
The Affiliated Hospital of Qingdao University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 53 Vulvar Neoplasms studies recruiting now, 39 (74%) set no upper age limit and 7 (13%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 6 · Phase 3 5
First in 2018; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 59 across 168 interventional studies indexed under Vulvar Neoplasms.
Median enrollment 54 across the 19 interventional studies, 2,836 across the 2 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 21 have an industry lead sponsor. The 10 most frequent:
Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Akeso has 1 study filed under Vulvar Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Vulvar Neoplasms with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04422366Phase 3Shanghai Bovax Biotechnology Co., Ltd.Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | 2027-09-15 |
| NCT07433283Sichuan Enray Pharmaceutical Sciences CompanyCarbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor | 2026-12-31 |
| NCT07424664Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyA Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer | 2027-03-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Vulvar Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open-label, phase II clinical study, aiming to the evaluate the efficacy and safety of AK104 (an anti- PD-1 and CTLA-4 bispecific antibody), alone or combined with chemotherapy, in subjects with recurrent or metastatic vulvar cancer not amenable to curative surgery or radiotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age >=18 and \<=80. of 0 or 2. ≥ 3 months. confirmed vulvar cancer (squamous cell carcinoma or adenosquamous carcinoma), not amenable to curative surgery or radical radiotherapy.
For Cohort A, subjects should have experienced failure on at least one previous systemic therapy, or intolerance to standard therapy.
At least one measurable tumor lesion per v1.1. Adequate organ function as assessed in the laboratory tests. Female subjects of must have a negative serum pregnancy test prior to the the first administration and agree to use effective methods of
Exclusion Criteria:
Subjects with other histopathological types of vulvar cancer, such as melanoma, sarcoma, etc.
Systemic or curative (surgery or radiotherapy) anti-tumor therapy within 4 weeks prior to the first administration.
Previous treatment with (e.g., anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, etc.).
Active or potentially recurrent disease.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AK104 monotherapy
Drug: AK104
AK104 combined with platinum-based chemotherapy (paclitaxel+ cisplatin or carboplatin)
Drug: AK104+ Paclitaxel+Cisplatin or Carboplatin
AK104 15mg/kg intravenously(IV) every 3 weeks (Q3W), until progressive disease, unacceptable toxicity, completion of 2 years treatment or withdrawal of consent.
Also known as: Cadonilimab
AK104 (10 mg/kg) + paclitaxel (175 mg/m2)+ cisplatin (50 mg/m2) or carboplatin (AUC 4-5) , IV, Q3W, for up to 6 cycles, followed by maintenance therapy of AK104 10 mg/kg Q3W until disease progression, intolerable toxicity, withdrawal of consent, or completion of 2 years treatment.
Objective response rate (ORR) assessed by investigator.
The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR per RECIST v1.1
Time frame: Up to approximately 1 years
Progression-free survival (PFS) Assessed by investigator
The time from the first administration to the first documented progressive disease (PD) or death due to any cause, whichever occurs first
Time frame: Up to approximately 2 years
Duration of Response (DOR) Assessed by investigator
Measured from the date of partial or complete response to therapy until the disease progression per RECIST v1.1 criteria
Time frame: Up to approximately 2 years
Disease control rate (DCR) Assessed by investigator
The proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥6 weeks) based on RECIST
Time frame: Up to approximately 1 years
Time to Response (TTR) Assessed by investigator
The time from the first administration to the date of documented CR or PR
Time frame: Up to approximately 1 years
Overall survival (OS)
The time from the first administration to death due to any cause
Time frame: Up to approximately 2 years
Adverse Events (AEs)
Characterization of incidence, severity and abnormal clinically significant manifestation or laboratory findings.
Time frame: Up to approximately 2 years
serum concentrations of AK104
assessment of PK include serum concentrations of AK104 at different timepoints after study drug administration
Time frame: Up to approximately 2 years
Antidrug antibodies (ADA) of AK104
Proportion of subjects who develop detectable anti-drug antibodies (ADAs)
Time frame: Up to approximately 2 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2023 to primary completion in May 2026, 33 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Dec 2025 → May 2026 and completion Dec 2025 → May 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Sponsor decision
Sponsor decision
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cadonilimab